LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Coherus Oncology Inc

Coherus Oncology Inc

Suletud

SektorTervishoid

1.56 -4.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.55

Max

1.56

Põhinäitajad
By Trading Economics
Sissetulek	-280M -38M
Müük	-438K 12M
P/E Sektori keskmine	3.509 51.415
Kasumimarginaal	-311.348
Töötajad	147
EBITDA	7.1M -36M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+406.13% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	33M 292M
Eelmine avamishind	5.85
Eelmine sulgemishind	1.56

Uudiste sentiment

By Acuity

50%

155 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.9209 / 1.05 Toetus ja vastupanu

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2026, 22:47 UTC

Kuumad aktsiad

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. mai 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. mai 2026, 22:00 UTC

Suurimad hinnamuutused turgudel

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. mai 2026, 18:09 UTC

Suurimad hinnamuutused turgudel

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15. mai 2026, 16:02 UTC

Tulu

Suurimad hinnamuutused turgudel

Forward Industries Shares Fall on New Debt as Solana Value Drops

15. mai 2026, 14:55 UTC

Suurimad hinnamuutused turgudel

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15. mai 2026, 14:43 UTC

Suurimad hinnamuutused turgudel

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15. mai 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. mai 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. mai 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 20:19 UTC

Kuumad aktsiad

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. mai 2026, 19:41 UTC

Omandamised, ülevõtmised, äriostud

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. mai 2026, 18:35 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15. mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15. mai 2026, 16:24 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15. mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15. mai 2026, 15:20 UTC

Tulu

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15. mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

406.13% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD 406.13%

Kõrge 12 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Coherus Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

155 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.